Latest news with #JeanMarcBellemin
Globe and Mail
17 hours ago
- Business
- Globe and Mail
Iovance Biotherapeutics CFO Resignation and Interim Appointment
Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Iovance Biotherapeutics ( (IOVA)) just unveiled an announcement. On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition. The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page. Spark's Take on IOVA Stock According to Spark, TipRanks' AI Analyst, IOVA is a Neutral. Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth. To see Spark's full report on IOVA stock, click here. More about Iovance Biotherapeutics Average Trading Volume: 13,697,268 Technical Sentiment Signal: Sell Current Market Cap: $581M See more data about IOVA stock on TipRanks' Stock Analysis page. Disclaimer & Disclosure Report an Issue
Yahoo
6 days ago
- Business
- Yahoo
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
The company's CFO resigned from his position. One law firm wasn't shy about reminding investors of the departure. 10 stocks we like better than Iovance Biotherapeutics › There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week was originally published by The Motley Fool Sign in to access your portfolio
Globe and Mail
27-06-2025
- Business
- Globe and Mail
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Bye-bye, says executive Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Adding to the struggles Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Should you invest $1,000 in Iovance Biotherapeutics right now? Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor 's total average return is1,048% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
